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The cancer/testis antigens (CTAs) are an important group of
heterogeneous proteins that are predominantly expressed in the
testis in the normal human adult but are aberrantly expressed in
several types of cancers. Prostate-associated gene 4 (PAGE4) is a
member of the CT-X family of CTAs that in addition to testis, is
highly expressed in the fetal prostate, and may also play an
important role both in benign and malignant prostate diseases.
However, the function of this gene remains poorly understood.
Here, we show that PAGE4 is a highly (100%) intrinsically dis-
ordered protein (IDP). The primary protein sequence conforms
to the features of a typical IDP sequence and the secondary
structure prediction algorithm metaPrDOS strongly supported
this prediction. Furthermore, SDS-gel electrophoresis and ana-
lytical size exclusion chromatography of the recombinant pro-
tein revealed an anomalous behavior characteristic of IDPs. UV
circular dichroism (CD) and NMR spectroscopy confirmed that
PAGE4 is indeed a highly disordered protein. In further bioin-
formatic analysis, the PredictNLS algorithm uncovered a
potential nuclear localization signal, whereas the algorithm
DBS-Pred returned a 99.1% probability that PAGE4 is a DNA-
binding protein. Consistent with this prediction, biochemical
experiments showed that PAGE4 preferentially binds a GC-
rich sequence. Silencing PAGE4 expression induced cell
death via apoptosis and in mice carrying PCa xenografts,
siRNA-mediated knockdown of the PAGE4 mRNA attenu-
ated tumor growth in vivo. Furthermore, overexpressing
PAGE4 protected cells from stress-induced death. To our
knowledge, PAGE4 is the first example of a CTA that is an
IDP with an anti-apoptotic function.
Contrary to the prevailing notion that most proteins are
globular with rigid three-dimensional conformations, many
biologically active proteins lack stable three-dimensional struc-
tures under physiological conditions in vitro. Such proteins,
referred to as intrinsically disordered proteins (IDPs),3 are
highly abundant in nature and possess a number of unique
structural properties such as high stability when exposed to low
pH and high temperature, and structural indifference toward
unfolding by strong denaturants (1).
Physiologically, IDPs are involved in signaling, and transcrip-
tional regulation, where binding to multiple partners and high
specificity/low affinity interactions play a crucial role. They
often function by molecular recognition, in which the disor-
dered segments are used for partner recognition (2). The bind-
ing segment undergoes induced folding to attain an ordered
structure upon binding to a biological target (coupled folding
and binding), and in addition, IDPs may structurally adapt to
different partners with different functional outcomes, resulting
in promiscuity in function termed “moonlighting” (3). Indeed,
the overexpression of IDPs is often associated with human dis-
eases, including cancer, cardiovascular disease, amyloidoses,
neurodegenerative diseases, and diabetes and thus, the IDPs
represent attractive targets for drugs modulating protein-pro-
tein interactions (4).
The cancer/testis antigens (CTAs) are an important group of
proteins that are predominantly expressed in the testis but
aberrantly expressed in several types of cancers (5). Because of
their restricted expression in an immune-privileged organ, the
CTAs represent attractive immunotherapy targets. Indeed,
autoantibodies against several CTAs have been detected in can-
cer patients and often such patients present with better prog-
nosis (6).
Broadly speaking, the CTAs can be divided into two groups:
the CT-X antigens located on the X chromosome and non-X
CT antigens located on various autosomes. The non-X CTAs
are fairlywell conservedwith known functions including, trans-
formation (7–9), chromatin remodeling (10–12), transcrip-
tional regulation (13–16), and signaling (17, 18) to name a few.
In contrast, the CT-X antigens appear to have evolved fairly
recently and most lack orthologues in lower mammals except
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particular are typically associated with advanced cancer with
poorer outcomes (20–25).
PAGE4 is a member of the PAGE family of CT-X antigens
that consists of several members that map to Xp11.21 on the X
chromosome. However, unlike a typical CT-X antigen that is
predominantly expressed only in the testis, PAGE4 appears to
be a developmental gene that is highly up-regulated in the fetal
prostate but is present at basal levels in the adult gland, both at
the protein4 and mRNA levels. However, PAGE4 is “reacti-
vated” in bothmalignant (26) and symptomatic but not asymp-
tomatic benign prostatic diseases (27). Despite these dynamic
expression patterns that parallel the proliferative growth of the
prostate gland during development and disease, the function of
PAGE4 remains poorly understood.
EXPERIMENTAL PROCEDURES
Bioinformatics Predictions—Disorder in the PAGE4 struc-
ture was predicted using FoldIndex (28), RONN (29), and
metaPrDOS (30). Nuclear localization signal (NLS) was pre-
dicted using the PredictNLS algorithm (31) and DNA binding
was predicted using the algorithm DBS-Pred (32).
Recombinant Protein Production—PAGE4 cDNA was
obtained by PCR using a cDNA clone (Origene, Rockville, MD)
as template and two gene-specific forward and reverse primers
containing NdeI and EcoRI restriction sites, respectively. Fol-
lowing restriction digestion, the cDNA was cloned into the
pET28a vector at the NdeI/EcoRI cloning sites resulting in its
in-frame fusion with an N-terminal His tag, and transfected
into the TOP10 Escherichia coli cells (Invitrogen). Expression
of the recombinant protein was induced with isopropyl 1-thio-
-D-galactopyranoside and protein was purified over a nickel
column from the supernatant obtained after bacterial lysis. The
eluted protein was digested with thrombin (EMD Biosciences,
SanDiego, CA) to remove theHis tag and again passed through
a nickel column to capture the His tag.
SDS-PAGE and Immunoblotting—The eluate was dialyzed
against PBS. Purified recombinant PAGE4 protein was ana-
lyzed on a NuPAGE 4–12% BisTris gel (Invitrogen) under
reducing and denaturing conditions and stained with Coomas-
sie Blue. Immunoblotting was done as described previously
(33). Total cellular lysate (50 g of protein) from LNCaP cells
was used to detect endogenous PAGE4. The polyclonal anti-
body was the same as described previously (25) and was used at
a 1:2,500 dilution overnight followed by incubation with sec-
ondary antibody at 1:50,000 dilution for 1 h.
Analytical Size Exclusion Chromatography—Samples were
injected into a Superdex 200 10/30 AKTA FPLC column (GE
Healthcare) using PBS as running buffer. Prior to PAGE4 chro-
matography, 200 g each of ovalbumin and ribonuclease A
were injected to serve as standards.
Biophysical Measurements—CD spectra were recorded at
the following temperatures: 5, 10, 15, 20, and 25 °C. A protein
concentration of 0.33 mg/ml was used in 10 mM sodium phos-
phate buffer containing 150 mM sodium chloride, pH 7.4. CD
measurements were made on a JASCO spectropolarimeter
using a 0.1-cm path length. One-dimensional 1H NMR spectra
of PAGE4 as a function of temperature were recorded on a
Bruker DMX-600 spectrometer using a protein concentration
of 1 mg/ml and the same buffer conditions as above. A water
flip-back pulse sequence was used for solvent suppression.
DNA Binding Studies—To determine whether PAGE4 binds
DNAand to identify the sequence towhich itmay preferentially
bind, we employed a technique we developed previously (34)
with somemodifications. A “library” of 10-mer dsDNAbinding
sites was constructed using a synthetic oligonucleotide 5-CG-
AGGTCGACGGTATCGNNNNNNNNNNGGATCCACTA-
GTTCTAGAGC-3 thatwas converted to dsDNAbyPCR. PCR
primers had the following sequences: P1, 5-CGAGGTCGAC-
GGTATCG-3; and P2, 5-GCTCTAGAACTAGTGGATC-3.
PCR was performed with GoTaq Green Master Mix (Pro-
mega, Madison, WI). PCR cycling conditions were 95 °C for
30 s, then 95 °C for 10 s, 62 °C for 30 s, and 72 °C for 1 s for 35
cycles. The PAGE4 protein was cloned into a FLAG-tagged-
pCMV6 (Origene, Rockville, MD), transiently expressed in
HEK293T cells (35), and purified by immunoprecipitation (36)
with FLAG-agarose beads (Sigma), using Frackelton buffer (10
mM Tris-HCl, 30 mM Na4P2O7, pH 7.1, 50 mM NaCl, 50 mM
NaF, HaltTM Protease Inhibitor Mixture (Thermo Scientific,
Rockford, IL)), containing 10 pmol of the dsDNA oligonucleo-
tide library. The agarose beads were washed 5 times with Tris-
buffered saline (TBS) and the DNA that co-immunoprecipi-
tated was extracted with a QIAEX II kit (Qiagen, Gaithersburg,
MD) and amplified with P1/P2 primers as described above. The
resulting PCR product was purified on a 2% agarose gel and
used in a new round of selection with PAGE4 protein. After the
third round of selection, the PCR product was cloned into pCR
NT/T7 TOPO TA vector (Invitrogen), plated on ampicillin-
containing agar plates. Twenty-five clones were randomly
selected to determine the DNA sequence of the binding sites.
Cell Culture—Prostate cancer cell lines were obtained from
the American Type Culture Collection (Rockville, MD). Cells
were cultured at 37 °C in routine RPMI (Invitrogen) medium
supplemented with 10% fetal bovine serum (FBS) with humid-
ified air and 5% carbondioxide. The LNCaP-96 cells used in this
study were those established at JohnsHopkinsUniversity by Pflug
et al. (37). They were routinely cultured in phenol-red free RPMI
supplemented with 10% charcoal-stripped FBS (HyClone, Logan,
UT).
In Vitro Studies—PAGE4 ON-TARGETplus SMARTpool
siRNA were obtained from Dharmacon (Lafayette, CO).
Approximately 5 103 cells were transfectedwith siRNAs at 50
nM total concentration using 0.2 l of DharmaFECT-3 of the
transfection reagent and plated in a 96-well plate. Drug treat-
ment was applied 24–48 h after transfection.
RNA Isolation and Q-RT PCR—Total RNA was isolated
using the RNeasy mini kit (Qiagen, Valencia, CA) following the
suppliers protocol. RNA samples were treated with DNase I
(Invitrogen), and cDNA was synthesized using the iScript
cDNA synthesis kit (Bio-Rad). Real-time PCR was done using
an iCycler iQMulticolor Real-time PCRDetection system (Bio-
Rad). PCR was done with RNA samples from a minimum of
three independent experiments and each PCR was set up in
triplicate. Target gene expression was compared with the
housekeeping gene TATA box-binding protein (TBP) for nor-4 R. H. Getzenberg, unpublished data.
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malization. The sequences of the PCR primers used were: TBP
forward, GAATATAATCCCAAGCGGTTTG; TBP reverse,
ACTTCACATCACAGCTCCCC; and PAGE4 forward, CGT-
AAAGTAGAAGGTGATTG, PAGE4 reverse, ATGCTTAGG-
ATTAGGTGGAG. PCR cycling conditions were 95 °C for 5
min, then 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s for 40
cycles.
Cell Viability and Inhibition Assay—Approximately 1 104
cells per well were seeded in 24-well plates. After growing for
1–7 days, the cell proliferation reagent WST-1 (4-[3-(4-iodo-
phenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzenedisul-
fonate) was added to each well, as specified by the supplier
(Roche Applied Science). After 4 h of incubation, WST-1
absorbance was measured at 450 nm. The cells were also stained
with 0.05%crystal violet plus 20%methanol. In someexperiments,
5 103 cells perwell were seeded in 96-well plates. Seventy-two h
after drug treatment, cell viability was analyzed by the WST-1
assay. Alternately, cell viability was evaluated by cell counting
using a hemocytometer after excluding dead cells by trypan blue
staining. All cell viability and inhibition experiments were biolog-
ical replicates repeated at least three times.
FlowCytometry—Apoptosis and cell cycle were detected on a
Guva system (Guava Technologies, Hayward, CA) using the
Terminal Transferase dUTP Nick End Labeling (TUNEL) kit
(GuavaTechnologies, Billerica,MA) andGuavaCell Cycle Rea-
gent (Guava Technologies), respectively.
Immunofluorescence—Twenty-five thousandcellswere seeded
in chamber slides. Seventy-two h after siRNA treatment, cells
were washed with PBS and fixed by 4% paraformalin, and then
incubated with phospho-histone H2A.X (-H2A.X) antibody
(Millipore, Billerica, MA) at room temperature for 1 h followed
by FITC-conjugated secondary antibodies. Slides were
observedwith aNikon Eclipse TE2000E using theGFP-BP filter
(Ex 460–500, DM 5005, DA:510–560) and analyzed with NIS
Elements AR 3.00 Software.
PAGE4 Overexpression—The entry vector containing the
PAGE4 open reading frame with C-terminal fusion of the DDK
tag, pCMV6-Entry, and destination vector pCMV6-AC-GFP
were purchased fromOrigene (Rockville, MD). The expression
vector pCMV6-PAGE4-GFP was generated by first digesting
pCMV6-Entry with SgfI andMluI digestion to extract the PAGE4
cDNA followed by in-frame ligation with destination vector
pCMV6-AC-GFP. Sequences of all constructs were verified by
SeqWrightDNATechnology Services (Houston, TX). These con-
structs were expressed inCWR22rv1 orHEK-293T cells by trans-
fection with FuGENEHD (Roche Applied Science).
FIGURE1.Bioinformaticpredictionsofdisorder in thePAGE4protein structure.A, amino acid sequenceof PAGE4. Polar residues are indicated ingreen and
non-polar residues are in red. The putative NLS and DNA-binding region are indicated by asterisks and underlines, respectively. Disorder in the PAGE4 protein
was predicted by FoldIndex (B), RONN (C), and metaPrDOS (D) as described under “Experimental Procedures.”
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In Vivo Treatments—For creating xenografts, 2  106
LNCaP cells suspended in 75 l of PBS were mixed with an
equal volume ofMatrigel and inoculated in the flank of 6-week-
old SCID mice (Harlan Sprague-Dawley). When tumor vol-
umes reached 200mm3, mice were divided into 3 groups with 7
animals per group and administered PAGE4 siRNA, scrambled
siRNA, or PBS treatment. siRNA was delivered using the Ate-
loGeneTM in vivo siRNA transfection kit (KOKEN, Japan), and
administrated intratumorally following the suppliers protocol
every 5 days for a total of 3 times. Tumor growth was measured
every 3 days and the relative tumor volumes were calculated as
described (38). Two days after the last treatment of siRNA, 2
mice in each group were sacrificed under ether anesthesia, and
tumors were dissected and frozen at80 °C in RNAlater until
further use. All treatment protocols were approved by the ani-
mal care and use committee of the Johns Hopkins University.
Statistical Analysis—Statistical comparisons were made
using the Student’s t test. Two-sided p  0.05 was considered
significant. All experiments were biological replicates repeated
a minimum of three times except in the case of the in vivo
experiments where they were done twice.
RESULTS ANDDISCUSSION
Predicting Disorder in PAGE4—Based on the relationships
among intrinsic disorder, sequence complexity as measured by
Shannon’s entropy, and amino acid composition, IDPs are typ-
ically thought to display a bias toward polar amino acids and a
bias away fromnon-polar amino acids (39). Indeed, as shown in
Fig. 1A, whereas the PAGE4 protein sequence was enriched in
polar and charged amino acids such as Gln, Ser, Pro, Glu, and
Lys, there was a distinct lack of bulky hydrophobic residues
such as Leu,Met, Phe, Trp, and Tyr. Thus, whereas the charged
residues constitute53% of the total protein, the hydrophobic
residues make up10% suggesting that PAGE4 may represent
an IDP (supplemental Table S1).
To further investigate this possibility, we applied two differ-
ent protein secondary structure prediction algorithms namely,
FoldIndex andRegionalOrderNeural Network (RONN) to dis-
cern disorder. FoldIndex developed by Prilusky et al. (28)
implements the algorithm described by Uversky et al. (40) to
make a calculation based on average net charge and average
hydrophobicity of the sequence to predict whether a given
sequence is ordered or disordered. In contrast, RONN uses a
neural network technique to predict whether any given residue
is likely to be ordered or disordered in the context of the sur-
rounding amino acid sequence. Although the physical proper-
ties of amino acids are the fundamental basis in determining
disorder, the neural network used in RONN avoids explicit
parameterization of amino acids in this way. Instead it uses
non-gapped sequence alignment to measure “distances”
between windows of sequence for the unknown protein and
windowed sequences for known folded proteins derived from
the Protein Data base (29). However, both FoldIndex and
RONN predicted 100% disorder in the PAGE4 protein struc-
ture (Fig. 1, B and C, respectively).
FIGURE 2. Anomalous behavior of PAGE4 protein in gel electrophoresis and analytical gel filtration chromatography. A, SDS-PAGE of recombinant
PAGE4 synthesized in bacteria. B, immunoblot showing anomalousmigration of the endogenous PAGE4 protein obtained fromLNCaP cells (lane 1, 50g) and
5g of recombinant PAGE4 (lane 2) using a anti-PAGE4-specific antibody. C and D, analytical size exclusion chromatography. Absorptions at 280 and 220 nm
were monitored as a function of retention volume and plotted with units shown on the left and right axis, respectively.
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To rule out any bias in the algorithms, we also used an addi-
tional prediction method namely, metaPrDOS. MetaPrDOS
uses a meta approach that does not predict disordered regions
from amino acid sequence directly but predicts them by inte-
grating the results of eight different prediction methods (30).
Consistent with the previous two algorithms, metaPrDOS also
predicted 100% disorder in the PAGE4 protein structure (Fig.
1D). Taken together, these data provided good evidence that
PAGE4 is an IDP.
Anomalous Behavior of PAGE4 Protein—To experimentally
confirm the extent of disorder, a recombinant form of PAGE4
was produced in bacteriawith an estimatedmolecularweight of
11,153 calculated from the conceptual ORF. However, its
mobility in SDS-PAGE suggested a size of 25 kDa (Fig. 2A). Size
exclusion chromatography under non-denaturing conditions
indicated an apparent molecular mass of 26 kDa and the pres-
ence of another species of 44 kDa suggesting potential
dimerization (Fig. 2, C and D). Such anomalous mobility of
IDPs is not uncommon (2). In SDS-PAGE, their mobility
appears to be retarded because of abnormally low SDS binding
to hydrophilic residues in the IDPs and, in size exclusion col-
umns, in contrast to the behavior of globular proteins, they
present extended conformations resulting in a larger than
expected Stokes radius. Anomalous behavior of the endoge-
nous PAGE4 protein as well as the purified recombinant pro-
tein was also confirmed by Western blotting with an anti-
PAGE4-specific antibody. As shown in Fig. 2B, the endogenous
protein exhibited amolecularmass of30 kDa, whereas that of
the recombinant protein was 25 kDa. The increase in the
weight of the endogenous protein presumably reflects some
kind of post-translational modification(s).
Biophysical Studies Confirm That PAGE4 Is an IDP—The
structural properties of PAGE4 in aqueous solution were char-
acterized qualitatively using circular dichroism (CD) and NMR
spectroscopy. CD spectra were recorded as a function of tem-
perature from 5 to 25 °C (Fig. 3A). These spectra showed that
the PAGE4 polypeptide chain contains no significant -helical
or -strand secondary structural elements over this tempera-
ture range as evidenced by low ellipticity values in the 215–230
nm region. One-dimensional 1H NMR spectra displayed a nar-
row chemical shift dispersion of amide proton signals, with
most resonances in the 7.0–8.5 ppm range (Fig. 3B). Narrow
dispersion of peaks was also present in the aliphatic methyl
region of the spectrum (data not shown). Resonances in the
amide and methyl regions of folded proteins are more spread
out due to ordered packing effects. Thus, the lack of signal dis-
persion is strongly indicative of a polypeptide chain with little
or no defined tertiary structure. Taken together, the CD and
NMR data show that PAGE4 does not have detectable second-
ary and tertiary structure, consistent with an IDP.
PAGE4 Contains a NLS and Is a Putative DNA-binding
Protein—The PredictNLS algorithm (31) identified a NLS in
the N terminus of PAGE4 (Fig. 1A, underlined) suggesting that
PAGE4 can potentially translocate into the nucleus, and the
algorithm DBS-Pred (32) returned a 99.1% probability that
PAGE4 is a DNA-binding protein. Furthermore, the DNA
binding region precisely overlapped with the NLS (Fig. 1A, Arg
residues are indicated by asterisks above the underline).
FIGURE 3. Biophysical characterization of PAGE4 disorder. A, circular
dichroism spectra of PAGE4 as a function of temperature. CD spectra were
recorded at the following temperatures: 5 (cyan), 10 (orange), 15 (green),
20 (red), and 25 °C (blue). A protein concentration of 0.33 mg/ml was used
in 10 mM sodium phosphate buffer containing 150 mM sodium chloride,
pH 7.4. CD measurements were made using a 0.1-cm path length. B, one-
dimensional 1H NMR spectra of PAGE4 as a function of temperature. The
amide proton region is shown. Spectra were recorded on a Bruker DMX-
600 using a protein concentration of 1 mg/ml and the same buffer condi-
tions as above. A water flip-back pulse sequence was used for solvent
suppression.
FIGURE 4. PAGE4 binds to a GC-rich DNA sequence. The DNA-binding
assay using purified FLAG-tagged PAGE4 protein was done as
described. A, dsDNA obtained by PCR. Lane 1, vector control; lane 2,
PAGE4; and lane 3, p53 positive control. B, the GC-rich consensus
sequences using the WebLogo software obtained from sequencing 33
independent clones.
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To confirm the DBS-Pred prediction that PAGE4 indeed
binds DNA, we challenged immunopurified PAGE4 protein
with a library of 10-mer DNA binding sites as described under
“Experimental Procedures.” Indeed, as shown in Fig. 4A,
whereas there was no “selection” of a dsDNA binding motif
with the GFP protein (lane 1), we observed enrichment of
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PAGE4 preferential binding sites when the PAGE4-FLAG pro-
tein was present (lane 3) as well as FLAG-p53, which was used
as a positive control. DNA sequence analysis revealed that
PAGE4 preferentially binds to a GC-rich sequence, 5-GCC-
GCGGGG-3 (Fig. 4). Thus, it is possible that PAGE4 is a tran-
scription factor or a sequence-specific DNA-binding protein
that is involved in aborting stress-induced apoptosis. Interest-
ingly, in amicroarray analysis, Iavarone et al. (26) observed that
the expression of lipoprotein lipase, a gene frequently deleted in
prostate cancer, is down-regulated in a cell line that overex-
presses PAGE4. It is thus plausible that PAGE4 could transcrip-
tionally regulate lipoprotein lipase expression in these cells.
However, additional experiments are required to uncover its
precise function.
Decreasing PAGE4 Attenuates Cell Survival—Up-regulation
of several CTAs including PAGE4 is associated with drug resis-
tance in cancer cells (41–44). Given the intrinsic nature of IDPs
to engage in promiscuous interactions and the presence of a
putative DNA-binding region in PAGE4, we hypothesized that
PAGE4 may play a critical role in cancer cells by mitigating the
genotoxic stress caused by cytotoxic drugs either by interacting
with key proteins or by directly binding DNA (or both). To test
this hypothesis, we determined the effect of down-regulating
PAGE4 expression on cell proliferation. First, we determined
the levels of PAGE4 mRNA in several normal and transformed
prostate cells by quantitative PCR and (supplemental Fig. S1)
and selected the following prostate cancer cell lines, LNCaP,
LN96, CWR22rv1, an embryonic cell line, HEK293T, and the
BPH cell line, BRF55, that express significant levels of PAGE4.
Transfecting these cells with a PAGE4-specific siRNA signifi-
cantly down-regulated (85–97.5%) PAGE4 mRNA compared
with the scrambled (control) siRNA (supplemental Fig. S2A).
Furthermore, by immunoblotting experiments using a FLAG-
tagged construct of PAGE4, we confirmed that the knockdown
resulted in decreased PAGE4 protein levels as well (supplemen-
tal Fig. S2B).
Next, the effect of silencing PAGE4 expression on prolifera-
tion of the siRNA-transfected cells was determined. As shown
in Fig. 5A and supplemental Fig. S3A, a WST-1 assay demon-
strated that siRNA-mediated down-regulation of PAGE4 sig-
nificantly impaired the proliferation of these cells in compari-
son to the scrambled siRNA. The decrease in proliferation was
also confirmed by staining cells with crystal violet. As shown in
Fig. 5B, whereas there was no discernable decrease in crystal
violet staining in cells transfected with the scrambled siRNA,
there was a significant decrease in cells that were transfected
with the PAGE4-specific siRNA when compared with non-
transfected control cells. We also determined the effects of
using a decreased dose of pooled PAGE4-specific siRNA (sup-
plemental Fig. S3B) or the individual siRNAs from the siRNA
pool (supplemental Fig. S3C). Indeed, both low concentra-
tions of the PAGE4-specific siRNA pool and individual
siRNAs that target different PAGE4 mRNA sequences
showed a similar effect in attenuating cell growth suggesting
that they specifically target PAGE4. Furthermore, we also
found that PAGE4 siRNA treatment showed little effect on
the growth of PC3 and LAPC4 cells both of which have
extremely low levels of PAGE4 mRNA (supplemental Fig.
S3D). Taken together, the data strongly suggest that siRNAs
used in the present study specifically target PAGE4 with no
discernable “off-target” effects.
FIGURE 5. Silencing PAGE4 expression inhibits cell survival and enhances chemo-cytotoxicity in prostate cancer cells. A, LNCaP, LNCaP-96, and
CWR22rv1 cells were transfected with 50 nM PAGE4 SMARTpool siRNA. Cell viability was evaluated byWST-1 assay 3–7 days after transfection. B, crystal violet
staining of CWR22rv1 cells 5 days after siRNA transfection. C, LNCaP cells was stainedwith propidium iodide 72 h after siRNA transfection and subjected to cell
cycle analysis. D, apoptosis of LNCaP cells was evaluated by TUNEL assay 72 h after siRNA transfection. E, immunofluorescence staining of -H2A.X in LNCaP
cells 72 h after siRNA transfection. Magnification is200 in all panels. F, the whole lysate of LNCaP cells were subjected to immunoblotting for p21, phospho-
p53 (Ser15) (pS-p53), and -H2A.X 72 h after siRNA transfection. Actin was used as a control for protein loading. G, LNCaP, LNCaP-96, and CWR22rv1 cells were
transfected with 50 nM PAGE4 SMARTpool siRNA. Forty-eight hours after transfection, cells were treated with ADM at the indicated dose for 4 h, and then
moved back to normal medium for another 16 h. Cell viability was evaluated byWST-1 assay. All experiments were biological replicates repeated aminimum
of three times. Data are represented as mean S.D. *, p 0.05 in comparison to scrambled-siRNA; #, p 0.05 in comparison to normal controls without any
treatment.
FIGURE 6. PAGE4 siRNA administration inhibits cell growth of LNCaP
xenografts in SCIDmice. A, SCID mice (seven in each group) were subcuta-
neously injectedwith 2106 LNCaP cells suspended inPBSandMatrigel, and
treated with PAGE4 siRNA by local injection every 5 days for 3 times. Mean
relative tumor volume of each group was plotted over time. B, two mice in
each group were sacrificed 2 days after the last administration of siRNA.
Tumor tissues were removed and subjected to RT-PCR to evaluate PAGE4
mRNA expression. Data are represented as mean  S.D. *, p  0.05 in com-
parison to scrambled siRNA treatment; #, p  0.05 in comparison to PBS
treatment.
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Silencing PAGE4 Results in Cell Death via Apoptosis—To
characterize the inhibition of cell growth by PAGE4 depletion,
cell cycle progression was then analyzed. Although the scram-
bled siRNA did not affect the cell cycle profile 3 days post-
transfection, PAGE4-specific siRNA increased the percentage
of cells in the G1/G0 phase by20% but decreased the percent-
age of cells in the S phase by 30% (Fig. 5C), suggesting that
PAGE4-depleted cells do not progress beyond this restriction
checkpoint and undergo apoptosis if they failed to reenter the
cell cycle. To examine whether apoptosis occurred following
PAGE4 knockdown, the number of TUNEL-positive cells
were determined. Indeed, TUNEL-positive cells were 5-fold
higher following PAGE4 knockdown than that seen with the
scrambled siRNA (Fig. 5D) confirming apoptosis. Further-
more, a significant accumulation of the variant histone
H2A.X, a hallmark of double strand breakage in cells
depleted of PAGE4 with the specific siRNA (Fig. 5E) but not
in scrambled siRNA-transfected cells provided good evi-
dence that in the absence of PAGE4, the arrested cells
undergo apoptosis.
To gain further insight into the mechanism of apoptosis fol-
lowing suppression of PAGE4 expression, immunoblotting
analyses were performed for p21, phosphorylated p53 as well as
H2A.X. Phosphorylation of H2A.X at serine 139 correlates
well with DNA damage and protein p21 is a potent cyclin-de-
pendent kinase inhibitor that binds to and inhibits the activity
of cyclin-CDK2 or -CDK4 complexes acting as a regulator of
cell cycle progression at G1. The expression of this gene is
tightly controlled by the tumor suppressor protein p53,
through which it mediates the p53-dependent cell cycle G1
phase arrest in response to a variety of stress stimuli. As
shown in Fig. 5F, there was a significant increase in the levels
of p21 and phospho-p53 upon PAGE4 suppression with a
concomitant increase in the accumulation of H2A.X sug-
FIGURE 7. Overexpression of PAGE4 protected cells from stress-induced death. HEK293T (A) and CWR22rv1 (B) cells were seeded in 6-well plates and
transfectedwith 4g of pCMV6-PAGE4-GFP vector (f) or empty vector pCMV6-GFP (). The number of living cells was counted using a hemocytometer after
excluding dead cells by trypan blue staining 1–5 days after transfection. C, Western blot for PARP-1, pS-p53, and PAGE4 protein in the cell lysate of the two cell
lines 72 h after transfection. Actin was blotted as loading control. D, CWR22rv1 cells were seeded in 12-well plates and transfected with pCMV6-GFP, pCMV6-
PAGE4-GFP, or pCMV6-PAGE4-GFP followed by 50 nM PAGE4 siRNA. Forty-eight hours after transfection, cells were treated with 1 g/ml of ADM for 4 h, and
thenmoved back to normal medium for another 19 h. Cell viability was evaluated byWST-1 assay.f, ADM treatment;, normal medium control. *, p 0.05
as compared with GFP-transfected cells; #, p  0.05 as compared with PAGE4-GFP plus PAGE4 siRNA-transfected cells. E, cells were lysed 24 h after ADM
treatment and subjected toWestern blot for PARP-1. Data are represented as mean S.D. All experiments were biological replicates repeated aminimum of
three times.
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gesting that PAGE4 plays roles in protecting against stress
and anti-apoptosis.
Silencing PAGE4 Expression Enhances Sensitivity of Prostate
Cancer Cells to Adriamycin—Because silencing PAGE4 expres-
sion alone resulted in significant cell death due to DNA dam-
age, a combined effect of siRNA-mediated knockdown and
cytotoxic drug treatmentwas evaluated. PCa cell lines thatwere
depleted of PAGE4 expression were treated with various con-
centrations of adriamycin, a commonly used cytotoxic drug
used to treat cancer. As shown in Fig. 5G, we observed a signif-
icant effect in cell survival. This effect was most pronounced in
LNCaP cells wherein,90% of the cells were killed at the high-
est drug dose compared with control siRNA transfected or
mock-transfected controls.
Knocking Down PAGE4 Attenuates Tumor Growth in Vivo—
To determine the in vivo effect of silencing PAGE4, we deter-
mined the effect of PAGE4 down-regulation on the growth of
PCa xenografts in SCIDmice. After the tumors were allowed to
develop for 4 weeks, siRNAwas administered intratumorally as
described under “Experimental Procedures.” Tumors that
received either PBS without any siRNA or those that included
the scrambled siRNA continued to grow, with tumor volume
reaching 8 102 mm3 (Fig. 6A). In contrast, there was signifi-
cant impairment in the growth of tumors that received PAGE4-
specific siRNA. To confirm that the decrease in tumor volume
was indeed due to PAGE4 silencing, PAGE4mRNA levels in the
tumors recovered from the animals 2 days after the last admin-
istration of siRNA were determined by quantitative PCR. As
shown in Fig. 6B, there was a dramatic decrease in PAGE4
mRNA in the tumor samples from animals treated with the
specific siRNA compared with the scrambled control. Taken
together, these in vitro and in vivodata suggest that PAGE4may
play an essential role in prostate cell survival.
Overexpressing PAGE4 Protects Cell Death—To elucidate the
effect of PAGE4 up-regulation under stress, we determined the
viability of CWR22rv1 and HEK-293T cells that were tran-
siently transfected with either a PAGE4-green fluorescent pro-
tein (PAGE4-GFP) construct or the empty vector carrying only
the GFP cDNA. In agreement with previous knockdown exper-
iments in that down-regulating PAGE4 levels decreased cell
survival, overexpression of PAGE4 significantly increased cell
viability in CWR22rv1 and HEK-293T cells following transient
transfection (Fig. 7A). Furthermore, overexpression of PAGE4
blocked the increase of poly(ADP-ribose) polymerase
(PARP-1) protein in the transfected cells, as well as activation of
p53 inHEK-293T cells, both ofwhich indicate a stress-response
suppression (18, 20) (Fig. 7B). To further evaluate the stress
protection of PAGE4 overexpression, we treated cells with
adriamycin. As expected, treating the empty vector-transfected
cells with the drug decreased their survival by 50%, whereas in
those transfected with the PAGE4 construct, cell viability was
decreased by 25% indicating a 50% increase in survival. In con-
trast, when PAGE4 expression was silenced using an siRNA,
survival dropped to 50% of the empty vector controls (Fig. 7C).
At the same time, the decrease of PARP-1 following drug treat-
ment in PAGE4 overexpressed cells was also reversed by siRNA
treatment suggesting that the stress protective status evidenced
by the reduced PARP-1 level in these cells is likely due to the
enhanced expression of PAGE4 (Fig. 7D). Taken together, the
result provides good evidence that PAGE4 favors cell survival
and protects cytotoxic stress in cells that typically overexpress
it.
CONCLUSION
To our knowledge, the present report is the first example of a
CTA that is an IDP. The inherent nature of IDPs to engage in
promiscuous interactions when present in increased concen-
trations is thought to be themechanism underlying their toxic/
pathologic effect (45). Furthermore, increasing disorder can
also tune the binding affinity of an IDP to maximize the speci-
ficity of promiscuous interactions (46).
Recently, Liu et al. (46) applying thermodynamic models of
protein interactions inwhich IDPs are characterized by positive
folding free energies presented a quantitative theory predicting
the role of intrinsic disorder in protein structure and function.
The authors predicted that both catalytic and low-affinity bind-
ing (Kd  107 M) proteins prefer ordered structures, whereas
only high-affinity binding proteins (found mostly in eukaryotes)
can tolerate disorder. Given the remarkable degree of disorder in
PAGE4, it is possible that by initiating promiscuous interactions,
PAGE4 may play a critical role in the disease process. Future
experiments that identify the interacting proteins should permit
further biophysical studies of the physiologically relevant confor-
mations accessed by PAGE4.
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